Tag: MatriSys

March 21, 2019 Off

MatriSys closer to begin testing MSB-01 for Atopic Dermatitis, afer FDA’s positive feedback

MatriSys Bioscience got positive feedback from the FDA on its planned initiation of clinical trials for MSB-01 under a U.S. IND for MatriSys’ lead microbiome-based candidate, MSB-01, for the treatment of Atopic Dermatitis (AD).

January 3, 2019 Off

MatriSys asks for meeting with FDA over anti-atopic dermatitis topical drug candidate

By Dino Mustafić

MatriSys Bioscience is waiting to meet with the US FDA to complete preparations for its company-sponsored Phase 2 trial of its anti-atopic dermatitis topical drug candidate, MSB-01, it said Wednesday.